Press Release

CAMK2 Therapeutics Network Awarded Chan Zuckerberg Initiative Rare As One Grant

October 4, 2024 – CAMK2 Therapeutics Network is excited to announce that it has been awarded the prestigious Rare As One Grant from the Chan Zuckerberg Initiative.

This significant grant will support its mission to build capacity within its patient-led rare disease organization and drive forward critical collaborative scientific research. The grant — totaling $800,000 — commenced on October 1, 2024, and extends through September 30, 2029.

During this period, CAMK2 Therapeutics Network will undertake several ambitious projects aimed at enhancing both organizational and scientific capacities within the rare disease community.

Key Projected Outcomes of the Grant:

- **Strengthening Organizational and Scientific Capacities:** Enhancing the infrastructure and capabilities of patient-led rare disease organizations to ensure more eVective and impactful research eVorts.
- **Assembling or Strengthening Collaborative Research Networks:** Building robust networks of basic researchers with a focus on channelopathies, ciliopathies, and inborn errors of metabolism (IEMs).
- **Convening the Disease Community:** Hosting scientific gatherings to bring together the disease community and foster an environment of collaboration and shared learning.
- **Developing a Patient-Prioritized Research Agenda:** Creating a research agenda that aligns with the top priorities of both researchers and patients within the disease area, ensuring that research eVorts are both relevant and impactful.
- **Active Participation in Rare As One Network:** Joining the Cycle 3 cohort and participating in regular calls, meetings, and collaborative eVorts with other organizations to foster cross-disease collaboration and support the development of shared scientific priorities and research projects.

“We are honored to receive this grant from the Chan Zuckerberg Initiative,” said Nev Ross, one of CAMK2 Therapeutics Network’s co-founders. “This support will enable us to significantly advance